Key facts
- BioSmartData’s last known valuation is $7.0M (Jul 2025).
- It has raised $1.6M; the latest was Later Stage VC in Jul 2026.
- Notable investors include Banco Santander, Elkargi, Enisa National Innovation Company, ICEX Next, Marisa Guitart.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for BioSmartData
- ·The full record, as it builds
Funding rounds
No funding rounds for BioSmartData are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioSmartData
Developer of a cloud-based healthcare analytics platform designed to support clinical decision-making through real-world data and artificial intelligence. The company offers tools for collecting structured data, generating real-world evidence, and validating treatment protocols, enabling healthcare professionals and medical device companies to improve patient outcomes, support regulatory compliance.
- Sector
- Healthcare
- HQ
- Marratxi, Spain
- Founded
- 2020
- Employees
- 12
- Website
- biosmartdata.eu/
- Ownership
- Privately Held (backing)
BioSmartData doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioSmartData shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioSmartData in its N-PORT filings yet. We sweep new filings monthly.